Skin manifestations of inflammatory bowel disease

Frontiers in Physiology

Volumn 3 FEB, Issue , 2012, Pages

  Huang, Brian L ^a   Chandra, Stephanie ^a   Shih, David Quan ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Crohn's disease; Inflammatory bowel disease; Skin disorders; Ulcerative colitis

Indexed keywords

EID: 84865717280     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2012.00013     Document Type: Review

References (128)

1. Abraham, C., and Medzhitov, R. (2011). Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 140, 1729-1737.
2. Adams, D. H., and Eksteen, B. (2006). Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat. Rev. Immunol. 6, 244-251.
3. Agrawal, D., Rukkannagari, S., and Kethu, S. (2007). Pathogenesis and clinical approach to extraintestinal manifestations of inflammatory bowel disease. Minerva Gastroenterol. Dietol. 53, 233-248.
4. Ahern, P. P., Izcue, A., Maloy, K. J., and Powrie, F. (2008). The interleukin23 axis in intestinal inflammation. Immunol. Rev. 226, 147-159.
5. Akbulut, S., Ozaslan, E., Topal, F., Albayrak, L., Kayhan, B., and Efe, C. (2008). Ulcerative colitis presenting as leukocytoclastic vasculitis of skin. World J. Gastroenterol. 14, 2448-2450.
6. Ali, M., and Duerksen, D. R. (2008). Ulcerative colitis and Sweet's syndrome: a case report and review of the literature. Can. J. Gastroenterol. 22, 296-298.
7. Alkhouri, N., Hupertz, V., and Mahajan, L. (2009). Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease. Inflamm. Bowel Dis. 15, 803-806.
8. Apgar, J. T. (1991). Newer aspects of inflammatory bowel disease and its cutaneous manifestations: a selective review. Semin. Dermatol. 10, 138-147.
9. Ardizzone, S., Puttini, P. S., Cassinotti, A., and Porro, G. B. (2008). Extraintestinal manifestations of inflammatory bowel disease. Dig. Liver Dis. 40(Suppl. 2), S253-S259.
10. Asarch, A., Barak, O., Loo, D. S., and Gottlieb, A. B. (2008). Th17 cells: a new therapeutic target in inflammatory dermatoses. J. Dermatolog. Treat. 19, 318-326.
11. Ashok, D., and Kiely, P. (2007). Bowel associated dermatosis arthritis syndrome: a case report. J. Med. Case Reports 1, 81.
12. Ayangco, L., Rogers, R. S. III., and Sheridan, P. J. (2002). Pyostomatitis vegetans as an early sign of reactivation of Crohn's disease: a case report. J. Periodontol. 73, 1512-1516.
13. Basu, M. K., and Asquith, P. (1980). Oral manifestations of inflammatory bowel disease. Clin. Gastroenterol. 9, 307-321.
14. Berkowitz, E. Z., and Lebwohl, M. (2000). Cutaneous manifestations of inflammatory bowel disease. J. Eur. Acad. Dermatol. Venereol. 14, 349-350.
15. Bernstein, C. N., Blanchard, J. F., Rawsthorne, P., and Yu, N. (2001). The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am.J.Gastroenterol. 96, 1116-1122.
16. Binus, A. M., Han, J., Qamar, A. A., Mody, E.A., Holt, E. W.,and Qureshi, A. A. (2011). Associated comorbidities in psoriasis and inflammatory bowel disease. J. Eur. Acad. Dermatol. Venereol. doi: 10.1111/j.1468-3083.2011.04153.x
17. Blitz, N. M., and Rudikoff, D. (2001). Pyoderma gangrenosum. Mt. Sinai J. Med. 68, 287-297.
18. Brooklyn, T. N., Dunnill, M. G., Shetty, A., Bowden, J. J., Williams, J. D., Griffiths, C. E., Forbes, A., Greenwood, R., and Probert, C. S. (2006). Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55, 505-509.
19. Cairns, B. A., Herbst, C. A., Sartor, B. R., Briggaman, R. A., and Koruda, M. J. (1994). Peristomal pyoderma gangrenosum and inflammatory bowel disease. Arch. Surg. 129, 769-772.
20. Callen, J. P. (1998). Pyoderma gangrenosum. Lancet 351, 581-585.
21. Callen, J. P., and Jackson, J. M. (2007). Pyoderma gangrenosum: an update. Rheum. Dis. Clin. North Am. 33, 787-802, vi.
22. Calobrisi, S. D., Mutasim, D. F., and Mcdonald, J. S. (1995). Pyostomatitis vegetans associated with ulcerative colitis. Temporary clearance with fluocinonide gel and complete remission after colec-tomy. OralSurg.OralMed. Oral Pathol. Oral Radiol. Endod. 79, 452-454.
23. Canpolat, F., Cemil, B. C., Yilmazer, D., Yesilli, O., and Eskioglu, F. (2011). Pyoderma vegetans associated with ulcerative colitis: a case with good response to steroids. CaseRep.Dermatol. 3, 80-84.
24. Chalvardjian, A., and Nethercott, J. R. (1982). Cutaneous granulomatous vasculitis associated with Crohn's disease. Cutis 30, 645-655.
25. Chen, M., O'toole, E. A., Sanghavi, J., Mahmud, N., Kelleher, D., Weir, D., Fairley, J. A., and Woodley, D. T. (2002). The epidermolysis bullosa acquisita antigen (type VII collagen) is present in human colon and patients with Crohn's disease have autoantibodies to type VII collagen. J. Invest. Dermatol. 118, 1059-1064.
26. Cho, J. H., and Brant, S. R. (2011). Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 140, 1704-1712.
27. Cohen, P. R. (2009). Neutrophilic dermatoses: a review of current treatment options. Am. J. Clin. Dermatol. 10, 301-312.
28. Cohen, P. R., and Kurzrock, R. (2002). Sweet's syndrome: a review of current treatment options. Am. J. Clin. Dermatol. 3, 117-131.
29. Cohen, P. R., and Kurzrock, R. (2003). Sweet's syndrome revisited: a review of disease concepts. Int. J. Dermatol. 42, 761-778.
30. Cohen, P. R., Talpaz, M., and Kurzrock, R. (1988). Malignancy-associated Sweet's syndrome: review of the world literature. J. Clin. Oncol. 6, 1887-1897.
31. Crowson, A. N., Mihm, M. C. Jr., and Magro, C. (2003). Pyoderma gangrenosum: a review. J. Cutan. Pathol. 30, 97-107.
32. Curley, R. K., Macfarlane, A. W., and Vickers, C. F. (1985). Pyoderma gangrenosum treated with Cyclosporine A. Br. J. Dermatol. 113, 601-604.
33. Danese, S., Semeraro, S., Papa, A., Roberto, I., Scaldaferri, F., Fedeli, G., Gasbarrini, G., and Gasbarrini, A. (2005). Extraintestinal manifestations in inflammatory bowel disease. World J. Gastroenterol. 11, 7227-7236.
34. Darvay, A. (1996). Sweet's syndrome preceding inflammatory bowel disease. Clin. Exp. Dermatol. 21, 175.
35. Das, K. M. (1999). Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig. Dis. Sci. 44, 1-13.
36. Diaz-Peromingo, J. A., Garcia-Suarez, F., Sanchez-Leira, J., and SaboridoFrojan, J. (2001). Sweet's syndrome in a patient with acute ulcerative colitis: presentation of a case and review of the literature. Yale J. Biol. Med. 74, 165-168.
37. Dronfield, M. W., Malone, J. D., and Langman, M. J. (1977). Zinc in ulcerative colitis: a therapeutic trial and report on plasma levels. Gut 18, 33-36.
38. Evans, P. E., and Pardi, D. S. (2007). Extraintestinal manifestations of inflammatory bowel disease: focus on the musculoskeletal, dermatologic, and ocular manifestations. MedGenMed 9, 55.
39. Farhi, D., and Wallach, D. (2008). The neutrophilic dermatoses. Dermatol. Nurs. 20, 274-282.
40. Fava, F., and Danese, S. (2011). Intestinal microbiota in inflammatory bowel disease: friend of foe? World J. Gastroenterol. 17, 557-566.
41. Feliciani, C., De Simone, C., and Amerio, P. (2009). Dermatological signs during inflammatory bowel diseases. Eur. Rev. Med. Pharmacol. Sci. 13(Suppl. 1), 15-21.
42. Femiano, F., Lanza, A., Buonaiuto, C., Perillo, L., Dell'ermo, A., and Cirillo, N. (2009). Pyostomatitis vegetans: a review of the literature. Med. Oral. Patol. Oral. Cir. Bucal. 14, E114-E117.
43. Ficarra, G., Baroni, G., and Massi, D. (2010). Pyostomatitis vegetans: cellular immune profile and expression of IL-6, IL-8 and TNF-alpha. Head Neck Pathol. 4, 1-9.
44. Fiorino, G., Allez, M., Malesci, A., and Danese, S. (2009). Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 29, 921-927.
45. Fleshner, P. R., Michelassi, F., Rubin, M., Hanauer, S. B., Plevy, S. E., and Targan, S. R. (1995). Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin. Dis. Colon Rectum 38, 1241-1245.
46. Freeman, H. J. (2005). Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease. Can. J. Gastroenterol. 19, 603-606.
47. Georgiou, G., Pasmatzi, E., Monastirli, A., and Tsambaos, D. (2006). Cutaneous manifestations of inflammatory bowel disease. Hosp. Chron. 1, 158-168.
48. Goudet, P., Dozois, R. R., Kelly, K. A., Ilstrup, D. M., and Phillips, S. F. (2001). Characteristics and evolution of extraintestinal manifestations associated with ulcerative colitis after proctocolectomy. Dig. Surg. 18, 51-55.
49. Guenova, E., Teske, A., Fehrenbacher, B., Hoerber, S., Adamczyk, A., Schaller, M., Hoetzenecker, W., and Biedermann, T. (2011). Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch. Dermatol. 147, 1203-1205.
50. Guhl, G., and Garcia-Diez, A. (2008). Subcutaneous sweet syndrome. Dermatol. Clin. 26, 541-551, viii-ix.
51. Hallopeau, H. (1898). "Pyodermitevegetante" ihre Beziehungen zur dermatitis herpetiformis und dem pemphigus vegetans. Arch. Dermatol. Syphilol. 43, 289-306.
52. Hansen, L. S., Silverman, S. Jr., and Daniels, T. E. (1983). The differential diagnosis of pyostomatitis vegetans and its relation to bowel disease. Oral Surg. Oral Med. Oral Pathol. 55, 363-373.
53. Hoffmann, R. M., and Kruis, W. (2004). Rare extraintestinal manifestations of inflammatory bowel disease. Inflamm. Bowel Dis. 10, 140-147.
54. Hue, S., Ahern, P., Buonocore, S., Kullberg, M. C., Cua, D. J., Mckenzie, B. S., Powrie, F., and Maloy, K. J. (2006). Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med. 203, 2473-2483.
55. Hundorfean, G., Neurath, M. F., and Sitaru, C. (2010). Autoimmunity against type VII collagen in inflammatory bowel disease. J. Cell. Mol. Med. 14, 2393-2403.
56. Iannone, F., Scioscia, C., Musio, A., Piscitelli, D., and Lapadula, G. (2003). Leukocytoclastic vasculitis as onset symptom of ulcerative colitis. Ann. Rheum. Dis. 62, 785-786.
57. Iborra, M., Beltran, B., Bastida, G., Aguas, M., and Nos, P. (2011). Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect. J. Crohns Colitis 5, 157-161.
58. Izcue, A., Coombes, J. L., and Powrie, F. (2009). Regulatory lymphocytes and intestinal inflammation. Annu. Rev. Immunol. 27, 313-338.
59. Jonas, M., and Scholefield, J. H. (2001). Anal fissure. Gastroenterol. Clin. North Am. 30, 167-181.
60. Jorizzo, J. L., Schmalstieg, F. C., Dinehart, S. M., Daniels, J. C., Cavallo, T., Apisarnthanarax, P., Rudloff, H. B., and Gonzalez, E. B. (1984). Bowel-associated dermatosis-arthritis syndrome. Immune complex-mediated vessel damage and increased neutrophil migration. Arch. Intern. Med. 144, 738-740.
61. Kaufman, I., Caspi, D., Yeshurun, D., Dotan, I., Yaron, M., and Elkayam, O. (2005). The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol. Int. 25, 406-410.
62. Kemmett, D., and Hunter, J. A. (1990). Sweet's syndrome: a clinicopathologic review of twenty-nine cases. J. Am. Acad. Dermatol. 23, 503-507.
63. Kethu, S. R. (2006). Extraintestinal manifestations of inflammatory bowel diseases. J. Clin. Gastroenterol. 40, 467-475.
64. Khor, B., Gardet, A., and Xavier, R. J. (2011). Genetics and pathogenesis of inflammatory bowel disease. Nature 474, 307-317.
65. Kitayama, A., Misago, N., Okawa, T., Iwakiri, R., and Narisawa, Y. (2010). Pyodermatitis-pyostomatitis vegetans after subtotal colectomy for ulcerative colitis. J. Dermatol. 37, 714-717.
66. Larsen, S., Bendtzen, K., and Nielsen, O. H. (2010). Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. Ann. Med. 42, 97-114.
67. Lebwohl, M., Fleischmajer, R., Janowitz, H., Present, D., and Prioleau, P. G. (1984). Metastatic Crohn's disease. J. Am. Acad. Dermatol. 10, 33-38.
68. Lebwohl, M., and Lebwohl, O. (1998). Cutaneous manifestations of inflammatory bowel disease. Inflamm. Bowel Dis. 4, 142-148.
69. Lees, C. W., Barrett, J. C., Parkes, M.,and Satsangi, J. (2011). New IBD genetics: common pathways with other diseases. Gut 60, 1739-1753.
70. Leibovitch, I., Ooi, C., Huilgol, S. C., Reid, C., James, C. L., and Selva, D. (2005). Pyodermatitispyostomatitis vegetans of the eyelids case report and review of the literature. Ophthalmology 112, 1809-1813.
71. Lestre, S., Ramos, J., Joao, A.,and Serrao, V. (2010). Cutaneous Crohn's disease presenting as genital warts: successful treatment with adalimumab. Eur. J. Dermatol. 20, 504-505.
72. Letsinger, J. A., Mccarty, M. A., and Jorizzo, J. L. (2005). Complex aphthosis: a large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomide. J. Am. Acad. Dermatol. 52, 500-508.
73. Levine, J. S., and Burakoff, R. (2011). Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol. Hepatol. (NY) 7,235-241.
74. Levitt, M. D., Ritchie, J. K., LennardJones, J. E.,and Phillips, R. K. (1991). Pyoderma gangrenosum in inflammatory bowel disease. Br. J. Surg. 78, 676-678.
75. Lewis, R. T., and Maron, D. J. (2010). Efficacy and complications of surgery for Crohn's disease. Gastroenterol. Hepatol. (NY) 6, 587-596.
76. Mackel, S. E., and Jordon, R. E. (1982). Leukocytoclastic vasculitis. A cutaneous expression of immune complex disease. Arch. Dermatol. 118, 296-301.
77. Marzano, A. V., Cugno, M., Trevisan, V., Fanoni, D., Venegoni, L., Berti, E., and Crosti, C. (2010). Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin. Exp. Immunol. 162, 100-107.
78. Matis, W. L., Ellis, C. N., Griffiths, C. E., and Lazarus, G. S. (1992). Treatment of pyoderma gangrenosum with cyclosporine. Arch. Dermatol. 128, 1060-1064.
79. McCarthy, F. P. (1949). Pyostomatitis vegetans; Report of three cases. Arch. Derm. Syphilol. 60, 750-764.
80. McClain, C., Soutor, C., and Zieve, L. (1980). Zinc deficiency: a complication of Crohn's disease. Gastroenterology 78, 272-279.
81. McGowan, J. W. T., Johnson, C. A., and Lynn, A. (2004). Treatment of pyoderma gangrenosum with etanercept. J. Drugs Dermatol. 3, 441-444.
82. Menachem, Y., and Gotsman, I. (2004). Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease. Isr. Med. Assoc. J. 6, 88-90.
83. Mert, A., Ozaras, R., Tabak, F., Pekmezci, S., Demirkesen, C., and Ozturk, R. (2004). Erythema nodosum: an experience of 10 years. Scand. J. Infect. Dis. 36, 424-427.
84. Mir-Madjlessi, S. H., Taylor, J. S., and Farmer, R. G. (1985). Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients. Am.J.Gastroenterol. 80, 615-620.
85. Mnif, L., Amouri, A., and Tahri, N. (2010). Cutaneous manifestations of inflammatory bowel disease. Tunis. Med. 88, 420-423.
86. Monsen, U., Sorstad, J., Hellers, G., and Johansson, C. (1990). Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am. J. Gastroenterol. 85, 711-716.
87. Monteleone, G., Pallone, F., and Macdonald, T. T. (2011). Emerging immunological targets in inflammatory bowel disease. Curr. Opin. Pharmacol. 11, 640-645.
88. Newell, L. M., and Malkinson, F. D. (1982). "Pyoderma (ecthyma) gangrenosum" by Brunsting, Goeckerman, and O'Leary, October 1930. Commentary: pyoderma gangrenosum. Arch. Dermatol. 118, 743-773.
89. Nischal, K. C., and Khopkar, U. (2007). An approach to the diagnosis of neutrophilic dermatoses: a histopathological perspective. Indian J. Dermatol. Venereol. Leprol. 73, 222-230.
90. Orchard, T. (2003). Extraintestinal complications of inflammatory bowel disease. Curr. Gastroenterol. Rep. 5, 512-517.
91. O'Sullivan, M., and O'Morain, C. (2006). Nutrition in inflammatory bowel disease. Best Pract. Res. Clin. Gastroenterol. 20, 561-573.
92. Pashankar, D., Prendiville, J., and Israel, D. M. (1999). Vitiligo and Crohn's disease in children. J. Pediatr. Gastroenterol. Nutr. 28, 227-229.
93. Passarini, B., Infusino, S. D., Barbieri, E., Varotti, E., Gionchetti, P., Rizzello, F., Morselli, C., Tambasco, R., and Campieri, M. (2007). Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumornecrosis-factor antibody therapy. Dermatology (Basel) 215, 295-300.
94. Patton, T., Jukic, D.,and Juhas, E. (2009). Atypical histopathology in bowelassociated dermatosis-arthritis syndrome: a case report. Dermatol. Online J. 15, 3.
95. Ploysangam, T., Heubi, J. E., Eisen, D., Balistreri, W. F., and Lucky, A. W. (1997). Cutaneous Crohn's disease in children. J. Am. Acad. Dermatol. 36, 697-704.
96. Quan, C., Ren, Y. Q., Xiang, L. H., Sun, L. D., Xu, A. E., Gao, X. H., Chen, H. D., Pu, X. M., Wu, R. N., Liang, C. Z., Li, J. B., Gao, T. W., Zhang, J. Z., Wang, X. L., Wang, J., Yang, R. Y., Liang, L., Yu, J. B., Zuo, X. B., Zhang, S. Q., Zhang, S. M., Chen, G., Zheng, X. D., Li, P., Zhu, J., Li, Y. W., Wei, X. D., Hong, W. S., Ye, Y., Zhang, Y., Wu, W. S., Cheng, H., Dong, P. L., Hu, D. Y., Li, Y., Li, M., Zhang, X., Tang, H. Y., Tang, X. F., Xu, S. X., He, S. M., Lv, Y. M., Shen, M., Jiang, H. Q., Wang, Y., Li, K., Kang, X. J., Liu, Y. Q., Sun, L., Liu, Z. F., Xie, S. Q., Zhu, C. Y., Xu, Q., Gao, J. P., Hu, W. L., Ni, C., Pan, T. M., Yao, S., He, C. F., Liu, Y. S., Yu, Z. Y., Yin, X. Y., Zhang, F. Y., Yang, S., Zhou, Y., and Zhang, X. J. (2010). Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nat. Genet. 42, 614-618.
97. Quezada, S., Turner, P. L., Alexiev, B., Daly, B., and Cross, R. (2009). Severe refractory orofacial Crohn's disease: report of a case. Dig. Dis. Sci. 54, 2290-2295.
98. Read, A. E. (1985). Pyoderma gangrenosum. Q. J. Med. 55, 99-101.
99. Roberts, N., and Bunker, C. (1993). The gut and the skin. Br.J.Hosp.Med.50, 31-39.
100. Rothfuss, K. S., Stange, E. F., and Herrlinger, K. R. (2006). Extraintestinal manifestations and complications in inflammatory bowel diseases. World J. Gastroenterol. 12, 4819-4831.
101. Safar, B., and Sands, D. (2007). Perianal Crohn's disease. Clin. Colon Rectal Surg. 20, 282-293.
102. Sarna, J., Sharma, A., and Marfatia, Y. S. (2008). Bilateral nonhealing ulcers in groin: an interesting case of Metastatic Crohn's disease. Indian J. Sex Transm. Dis. 29, 98-100.
103. Sattianayagam, P. T., Hawkins, P. N., and Gillmore, J. D. (2009). Systemic amyloidosis and the gastrointestinal tract. Nat. Rev. Gastroenterol. Hepatol. 6, 608-617.
104. Ship, J. A. (1996). Recurrent aphthous stomatitis. An update. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 81, 141-147.
105. Singh, S., Graff, L. A., and Bernstein, C. N. (2009). Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am. J. Gastroenterol. 104, 1298-1313; quiz 1314.
106. Souissi, A., Benmously, R., Fenniche, S., Zarrouk, M., Marrek, H., Debbiche, A., Ayed, M. B., and Mokhtar, I. (2007). Sweet's syndrome: a propos of 8 cases. Tunis. Med. 85, 49-53.
107. Storwick, G. S., Prihoda, M. B., Fulton, R. J., and Wood, W. S. (1994). Pyodermatitis-pyostomatitis vegetans: a specific marker for inflammatory bowel disease. J. Am. Acad. Dermatol. 31, 336-341.
108. Thornton, J. R., Teague, R. H., Low-Beer, T. S., and Read, A. E. (1980). Pyoderma gangrenosum and ulcerative colitis. Gut 21, 247-248.
109. Timani, S., and Mutasim, D. F. (2008). Skin manifestations of inflammatory bowel disease. Clin. Dermatol. 26, 265-273.
110. Tromm, A., May, D., Almus, E., Voigt, E., Greving, I., Schwegler, U., and Griga, T. (2001). Cutaneous manifestations in inflammatory bowel disease. Z. Gastroenterol. 39, 137-144.
111. Trost, L. B., and McDonnell, J. K. (2005). Important cutaneous manifestations of inflammatory bowel disease. Postgrad. Med. J. 81, 580-585.
112. Tsiamoulos, Z., Karamanolis, G., Polymeros, D., Triantafyllou, K., and Oikonomopoulos, T. (2008). Leukocytoclastic vasculitis as an onset symptom of Crohn's disease. Case Rep. Gastroenterol. 2, 410-414.
113. Tu, J., Chan, J. J., and Yu, L. L. (2011). Bowel bypass syndrome/bowelassociated dermatosis arthritis syndrome post laparoscopic gastric bypass surgery. Australas. J. Dermatol. 52, e5-e7.
114. Turkcapar, N., Toruner, M., Soykan, I., Aydintug, O. T., Cetinkaya, H., Duzgun, N., Ozden, A., and Duman, M. (2006). The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease. Rheumatol. Int. 26, 663-668.
115. Turner, R. B., Emer, J. J., Weill, M., Winterfield, L., Friedman, S., and Qureshi, A. A. (2010). Rapid resolution of pyoderma gangrenosum after treatment with intravenous cyclosporine. J. Am. Acad. Dermatol. 63, e72-e74.
116. Tutrone, W. D., Green, K., Weinberg, J. M., Caglar, S., and Clarke, D. (2007). Pyoderma gangrenosum: dermatologic application of hyperbaric oxygen therapy. J. Drugs Dermatol. 6, 1214-1219.
117. van Wijk, F., and Cheroutre, H. (2010). Mucosal T cells in gut homeostasis and inflammation. Expert Rev. Clin. Immunol. 6, 559-566.
118. Vavricka, S. R., Brun, L., Ballabeni, P., Pittet, V., Prinz Vavricka, B. M., Zeitz, J., Rogler, G., and Schoepfer, A. M. (2011). Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am.J.Gastroenterol. 106, 110-119.
119. Veloso, T. (1990). Complement deposits in inflammatory bowel disease. Gastroenterology 99, 1541-1542.
120. Vij, A., Modi, G. M., Suwattee, P., Cockerell, C. J., and Hsu, S. (2010). Chronic, recurrent neutrophilic dermatosis: a case report. Dermatol. Online J. 16, 1.
121. Vind, I., Riis, L., Jess, T., Knudsen, E., Pedersen, N., Elkjaer, M., Bak Andersen, I., Wewer, V., Norregaard, P., Moesgaard, F., Bendtsen, F., and Munkholm, P. (2006). Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn's colitis database. Am. J. Gastroenterol. 101, 1274-1282.
122. von Felbert, V., and Hunziker, T. (2010). Acrodermatitis enteropathica-like skin lesions due to Crohn's diseaseassociated zinc deficiency. Hautarzt 61, 927-929.
123. Wasserteil, V., Bruce, S., Sessoms, S. L., and Guntupalli, K. K. (1992). Pyoderma gangrenosum treated with hyperbaric oxygen therapy. Int. J. Dermatol. 31, 594-596.
124. Weinstein, M., Turner, D., and Avitzur, Y. (2005). Erythema nodosum as a presentation of inflammatory bowel disease. CMAJ 173, 145-146.
125. Williams, H., Walker, D., and Orchard, T. R. (2008). Extraintestinal manifestations of inflammatory bowel disease. Curr. Gastroenterol. Rep. 10, 597-605.
126. Wittekindt, C., Luers, J. C., Klussmann, J. P., and Huttenbrink, K. B. (2007). Pyoderma gangrenosum in the head and neck. Arch. Otolaryngol. Head Neck Surg. 133, 83-85.
127. Wollina, U. (2002). Clinical management of pyoderma gangrenosum. Am. J. Clin. Dermatol. 3, 149-158.
128. Yates, V. M., Watkinson, G., and Kelman, A. (1982). Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis. Br. J. Dermatol. 106, 323-330.